

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6969797

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
UMC UTRECHT HOLDING B.V.	09/30/2021
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	TIGA TX, INC.
<b>Street Address:</b>	27 PASADENA AVE.
<b>City:</b>	WESTERLY
<b>State/Country:</b>	RHODE ISLAND
<b>Postal Code:</b>	02891
<b>PROPERTY NUMBERS Total: 9</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	16329726
Application Number:	16825563
Application Number:	17132989
Application Number:	62824864
Patent Number:	11091562
Patent Number:	11059909
Application Number:	17343232
Application Number:	17343249
Application Number:	62865495
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)310-6001
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6173106000
<b>Email:</b>	smithray@gtlaw.com, BOSIPMAIL@GTLAW.COM
<b>Correspondent Name:</b>	GREENBERG TRAUIG, LLP (BOS)
<b>Address Line 1:</b>	ONE INTERNATIONAL PLACE, SUITE 200
<b>Address Line 2:</b>	ATTN: PATENT ADMINISTRATOR
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02110
<b>ATTORNEY DOCKET NUMBER:</b>	199828
<b>NAME OF SUBMITTER:</b>	DAVID MATA

PATENT

<b>SIGNATURE:</b>	/David Mata/
<b>DATE SIGNED:</b>	10/14/2021
<b>Total Attachments: 5</b> source=Executed Corporate to Corporate Assignment of Entire Interest (UMCU to TigaTX)#page1.tif source=Executed Corporate to Corporate Assignment of Entire Interest (UMCU to TigaTX)#page2.tif source=Executed Corporate to Corporate Assignment of Entire Interest (UMCU to TigaTX)#page3.tif source=Executed Corporate to Corporate Assignment of Entire Interest (UMCU to TigaTX)#page4.tif source=Executed Corporate to Corporate Assignment of Entire Interest (UMCU to TigaTX)#page5.tif	

**UMC Utrecht Holding B.V.**, a private company with limited liability (*besloten vennootschap met beperkte aansprakelijkheid*) existing under Dutch law, having a place of business at Yalelaan 40, 3584 CM Utrecht, the Netherlands, registered with the Trade Register under number 30139053 (the "Assignor"), desires to assign the entire right, title and interest in and to the Inventions and Assigned Patents (as defined in the attached Appendix) to **TigaTX, Inc.**, a corporation incorporated under the laws of the state of Delaware, having a place of business at 27 Pasadena Avenue, Westerly, RI 02891, (the "Assignee"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor has obtained the entire right, title and interest in and to certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s):

**SEE SCHEDULE**

- for which application serial number SEE SCHEDULE was filed on SEE SCHEDULE in the United States Patent and Trademark Office
- for which a PCT application serial number SEE SCHEDULE was filed on SEE SCHEDULE in the Office of the Patent Cooperation Treaty
- for which application serial number SEE SCHEDULE was filed on SEE SCHEDULE in the SEE SCHEDULE Patent Office
- for which an application was filed and upon which a United States Patent issued on SEE SCHEDULE as U.S. Patent No. SEE SCHEDULE

(the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

2. Said Assignor does hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.

3. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Assignor in providing such cooperation shall be paid for by said Assignee.

4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, and assigns, and shall be binding upon said Assignor and its assigns.


5. Said Assignor hereby warrants, represents and covenants that Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

6. Said Assignor hereby requests that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors and assigns.


7. This instrument will be interpreted and construed in accordance with Dutch laws, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below:

AGREED TO BY ASSIGNOR:

Date: 30-09-2021 Signature:   
Name: T.V. Scharringhansen  
Title: Director

RECEIVED AND AGREED TO BY ASSIGNEE:

Date: October 1st, 2021 Signature:   
Name: Anne Altmeyer  
Title: CEO

**SCHEDULE**

Patent Application Title	Country	Filed Date	Application Number	Grant Date	Patent No.
CD20 ANTIBODIES	PCT	2017-09-01	PCT/NL17/50581		
CD20 ANTIBODIES	EP	2016-09-01	16186850.0		
CD20 ANTIBODIES	EP	2017-09-01	17762244.6		
CD20 ANTIBODIES	Australia	2017-09-01	2017320457		
CD20 ANTIBODIES	Canada	2017-09-01	3035427		
CD20 ANTIBODIES	China	2017-09-01	201780064749.4		
CD20 ANTIBODIES	Japan	2017-09-01	2019511980		
CD20 ANTIBODIES	Mexico	2017-09-01	MX/a/2019/002417		
CD20 ANTIBODIES	New-Zealand	2017-09-01	751314		
CD20 ANTIBODIES	US	2017-09-01	16/329,726		
ANTI-GD2 ANTIBODY FOR THE TREATMENT OF NEUROBLASTOMA	US	2018-09-21	16/825,563		
ANTI-GD2 ANTIBODY FOR THE TREATMENT OF NEUROBLASTOMA	Australia	2018-09-21	2018336017		
ANTI-GD2 ANTIBODY FOR THE TREATMENT OF NEUROBLASTOMA	Australia	To be filed	To be filed		
ANTI-GD2 ANTIBODY FOR THE TREATMENT OF NEUROBLASTOMA	Brazil	2018-09-21	BR 11 2020 005742 8		
ANTI-GD2 ANTIBODY FOR THE TREATMENT OF NEUROBLASTOMA	Canada	2018-09-21	3,076,482		
ANTI-GD2 ANTIBODY FOR THE TREATMENT OF NEUROBLASTOMA	China	2018-09-21	201880065543.8		
ANTI-GD2 ANTIBODY FOR THE TREATMENT OF NEUROBLASTOMA	US	2020-12-23	17/132,989		
ANTI-GD2 ANTIBODY FOR THE TREATMENT OF NEUROBLASTOMA	PCT	2018-09-21	PCT/NL18/050629		
ANTI-GD2 ANTIBODY FOR THE TREATMENT OF NEUROBLASTOMA	EP	2017-09-21	17192476.4		
ANTI-GD2 ANTIBODY FOR THE TREATMENT OF NEUROBLASTOMA	EP	2018-09-21	18812321.0		
ANTI-GD2 ANTIBODY FOR THE TREATMENT OF NEUROBLASTOMA	Hong Kong	2018-09-21	62020022584.0		
ANTI-GD2 ANTIBODY FOR THE TREATMENT OF NEUROBLASTOMA	Israel	2018-09-21	273454		
ANTI-GD2 ANTIBODY FOR THE	India	2018-09-21	202027011912		

## SCHEDULE

TREATMENT OF NEUROBLASTOMA					
ANTI-GD2 ANTIBODY FOR THE TREATMENT OF NEUROBLASTOMA	Japan	2018-09-21	2020-538517		
ANTI-GD2 ANTIBODY FOR THE TREATMENT OF NEUROBLASTOMA	South Korea	2018-09-21	10-2020-7011096		
ANTI-GD2 ANTIBODY FOR THE TREATMENT OF NEUROBLASTOMA	Mexico	2018-09-21	MX/a/2020/003201		
ANTI-GD2 ANTIBODY FOR THE TREATMENT OF NEUROBLASTOMA	New Zealand	2018-09-21	762835		
ANTI-GD2 ANTIBODY FOR THE TREATMENT OF NEUROBLASTOMA	Singapore	2018-09-21	11202002581W		
ANTI-GD2 ANTIBODY FOR THE TREATMENT OF NEUROBLASTOMA	South Africa	2018-09-21	2020/01805		
ENGINEERED IGA ANTIBODIES AND METHODS OF USE	US	2019-03-27	62/824,864		
ENGINEERED IGA ANTIBODIES AND METHODS OF USE	US	2020-11-06	17/091,890	2021-08-17	11,091,562
ENGINEERED IGA ANTIBODIES AND METHODS OF USE	US	2020-11-06	17/091,897	2021-07-13	11,059,909
ENGINEERED IGA ANTIBODIES AND METHODS OF USE	US	2021-06-09	17/343,232		
ENGINEERED IGA ANTIBODIES AND METHODS OF USE	US	2021-06-09	17/343,249		
ENGINEERED IGA ANTIBODIES AND METHODS OF USE	PCT	2020-03-27	PCT/NL20/050217		
ENGINEERED IGA ANTIBODIES AND METHODS OF USE	AU	<i>To be filed</i>			
ENGINEERED IGA ANTIBODIES AND METHODS OF USE	CA	<i>To be filed</i>			
ENGINEERED IGA ANTIBODIES AND METHODS OF USE	CN	<i>To be filed</i>			
ENGINEERED IGA ANTIBODIES AND METHODS OF USE	EP	<i>To be filed</i>	20717331.1		
ENGINEERED IGA ANTIBODIES AND METHODS OF USE	IL	<i>To be filed</i>			
ENGINEERED IGA ANTIBODIES AND METHODS OF USE	JP	<i>To be filed</i>			
ENGINEERED IGA ANTIBODIES AND METHODS OF USE	KR	<i>To be filed</i>			
ENGINEERED IGA ANTIBODIES AND METHODS OF USE	SG	<i>To be filed</i>			

SCHEDULE

IMMUNE CELLS ENGAGER POLYPEPTIDE CONSTRUCTS AND METHODS OF USE	US	2019-06-24	62/865,495		
---	----	------------	------------	--	--